Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

Ustekinumab

(2009) Anna L. Chien et al.   DRUGS

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

(2008) M A Giembycz   BRITISH JOURNAL OF PHARMACOLOGY

PDE4 inhibitors: current status

(2008) D Spina   BRITISH JOURNAL OF PHARMACOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

The role of calcium/calmodulin-dependent protein kinase cascade on MIP-1α gene expression of ATL cells

(2008) Kensuke Matsumoto et al.   EXPERIMENTAL HEMATOLOGY